CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration has approved JOURNAVX, an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor ...

Vertex CEO Reshma Kewalramani described the FDA ... Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals.

U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its ...

CEO Dr. Reshma Kewalramani said Journavx ... Journavx in the U.S. would be $15.50 per 50mg pill. The news sent Vertex Pharmaceuticals shares, which had been up just 1% over the past 12 months ...

Vertex Pharmaceuticals' non-opioid painkiller received ... for the treatment of adults with moderate-to-severe acute pain." CEO Dr. Reshma Kewalramani said Journavx was "the first new class ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...